Bactrim Dosing for Adult Skin and Soft Tissue Infections
For uncomplicated skin and soft tissue infections in adults, prescribe Bactrim DS (double-strength) 1–2 tablets twice daily for 7 days, with the higher dose (2 tablets twice daily) reserved for more severe infections or when MRSA is suspected. 1
Standard Dosing Regimen
- Oral therapy: 1–2 double-strength tablets (160 mg trimethoprim/800 mg sulfamethoxazole per tablet) twice daily 2, 1
- Duration: Typically 7 days based on clinical response 1
- Severe infections requiring IV therapy: 8–12 mg/kg/day (based on trimethoprim component) divided into 4 doses IV, or 5 mg/kg/dose IV every 8–12 hours 1
Clinical Context and Appropriate Use
Bactrim is specifically indicated for purulent cellulitis where MRSA is suspected, but should NOT be used as monotherapy for non-purulent cellulitis because it has poor activity against beta-hemolytic streptococci, which are the primary pathogens in non-purulent infections. 1
- For mixed aerobic-anaerobic wound infections, Bactrim lacks anaerobic coverage and requires combination therapy 1
- The Infectious Diseases Society of America guidelines support Bactrim as an effective option for MRSA skin infections 2, 3
High-Dose vs. Standard-Dose Considerations
Research comparing high-dose (320 mg/1,600 mg twice daily) versus standard-dose (160 mg/800 mg twice daily) TMP-SMX found no difference in clinical resolution rates (73% vs 75%, p=0.79) for MRSA skin infections treated for 7–15 days. 4 However, high-dose therapy carries significantly higher risk of adverse effects:
- Hyperkalemia: 3.46% vs 0.81% (p=0.0066) 5
- Acute kidney injury: 3.67% vs 1.63% (p=0.044) 5
- Rash: 1.83% vs 0.20% (p=0.021) 5
- Overall ADR rate: 13.0% vs 5.09% (p<0.0001) 5
Given equivalent efficacy but substantially higher toxicity, standard-dose therapy (1 DS tablet twice daily) is preferred for most uncomplicated skin infections, reserving 2 DS tablets twice daily only for severe or complicated cases. 4, 5
Renal Impairment Adjustments
Dose adjustment is not required until creatinine clearance falls below 30 mL/min, as TMP and SMX disposition remain largely unchanged above this threshold. 6
- CrCl 15–30 mL/min: Reduce dose by 50% 6
- CrCl <15 mL/min: Use is not recommended, though not absolutely contraindicated; if used, reduce dose by 50% and monitor closely 6
- Hemodialysis: Administer after dialysis sessions 6
Critical Safety Monitoring
Acute kidney injury occurs in approximately 11% of patients receiving ≥6 days of TMP-SMX therapy, with 5.8% of cases directly attributable to the drug. 7 Risk factors include:
- Advanced age 5
- Concomitant ACE inhibitor or ARB use (independent risk factor for hyperkalemia) 5
- Pre-existing hypertension and diabetes mellitus, especially if poorly controlled 7
For patients with these risk factors, consider baseline and follow-up monitoring of serum creatinine, BUN, and potassium within 5–7 days of initiating therapy. 7, 5 Most cases of AKI resolve promptly after discontinuation. 7
Absolute Contraindications
- Third trimester of pregnancy (kernicterus risk) 1
- Nursing mothers 1
- Documented sulfa allergy 1
- Megaloblastic anemia due to folate deficiency 8
Transition from IV to Oral Therapy
Switch from IV to oral when the patient demonstrates clinical improvement, can tolerate oral intake, and does not have malabsorption or diarrhea. 1 Use the same total daily dose when transitioning. 1